Ezetimibe-Simvastatin Therapy Reduce Recurrent Ischemic Stroke Risks in Type 2 Diabetic Patients

Area of Science:

• Cardiology
• Neurology
• Endocrinology

Background:

• Statins are primary lipid-lowering agents for type 2 diabetes mellitus (T2DM).
• Ezetimibe-simvastatin (EZ-SIM) shows potential cardiovascular benefits in acute coronary syndrome.
• Diabetic stroke patients require effective secondary prevention strategies.

Purpose of the Study:

• To evaluate the efficacy of ezetimibe-simvastatin (EZ-SIM) combination therapy versus atorvastatin (ATOR) and simvastatin (SIM) for stroke prevention in diabetic patients.
• To compare the risk of recurrent ischemic stroke (IS), myocardial infarction, and all-cause mortality among different lipid-lowering therapies.

Main Methods:

• Retrospective cohort study using Taiwan's National Health Insurance Research Database (2009-2011).
• Patients with T2DM admitted for IS were categorized into EZ-SIM, ATOR, and SIM groups.
• Follow-up for 34 months to assess primary outcomes: recurrent IS, myocardial infarction, and death.

Main Results:

• The risk of recurrent IS was significantly higher in the SIM group compared to ATOR (HR 2.03) and EZ-SIM (HR 1.69).
• No significant difference in recurrent IS risk was observed between EZ-SIM and ATOR (HR 1.20).
• Composite endpoint incidence was highest in the SIM group (28.2%) versus ATOR (16.1%) and EZ-SIM (15.4%).

Conclusions:

• High-potency lipid-lowering therapies, including EZ-SIM and ATOR, are effective in reducing recurrent IS risk in diabetic patients.
• Combination therapy with ezetimibe and simvastatin demonstrates comparable efficacy to atorvastatin for stroke prevention.